CoChat

Assessing the clinical, humanistic, and economic impact of early cancer diagnosis: a systematic literature review

Open access
Aguiar-Ibáñez, Raquel, Mbous, Yves Paul Vincent, Sharma, Sugandh, Chawla, Evanka · 2025 · Frontiers in Oncology

The DOI matches its Crossref record; 105 of the 107 references it cites were found in a registry or an index.

Abstract

Introduction: There is a clear consensus among healthcare providers on the advantages of early cancer detection and treatment. However, no in-depth review has yet fully presented the clinical, humanistic, and economic benefits of early cancer diagnosis compared to late detection across a broad range of tumor types. Methods: A systematic literature review was conducted to determine the clinical, humanistic, and economic benefits of early cancer diagnosis, as opposed to late diagnosis, as reported in non-interventional studies conducted worldwide. Searches were conducted using electronic databases (MEDLINE and Embase), conference repositories and grey literature. Observational studies in adults diagnosed with bladder cancer, gastric cancer, head and neck cancer (HNC), melanoma, non-small cell lung cancer (NSCLC), renal-cell carcinoma (RCC), and triple negative breast cancer (TNBC) were eligible for inclusion if they reported survival, health-related quality of life (HRQoL), healthcare resource utilization and/or costs, according to stage at diagnosis. Identified records were screened and extracted by two independent reviewers, and discrepancies were resolved by a third reviewer. The quality of studies was assessed using the Newcastle-Ottawa scale and the Larg and Moss adapted checklist. Results: Of the 3,159 records identified, 103 studies were included in this review. The general trend showed worse clinical, humanistic, and economic outcomes when patients were diagnosed at a later stage compared to an earlier stage. Patients diagnosed at an earlier stage, had on average, substantially higher survival rates and lower mortality rates across all cancer types and incurred lower resource utilization and costs (with available evidence for patients with NSCLC, TNBC, and HNC), compared to those diagnosed at a more advanced/later stage. Limited evidence on the humanistic burden suggested that with a more advanced stage at diagnosis, patients with bladder cancer experienced reduced HRQoL. Conclusion: Early cancer diagnosis (i.e., cancer diagnosed at earlier stages or with lower grades) was associated with longer survival, improved quality of life and lower healthcare costs and resource utilization compared to diagnosis of cancer at later stages or higher grades, as reported by overall survival (OS) and HRQoL outcomes. These findings emphasize the importance of screening and early detection of cancer to improve outcomes among patients diagnosed with cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2025.1546447

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PRISMA flow diagram. *60 unique studies included across the clinical, humanistic, and economic reviews, where 32 unique studies were not included as the outcomes were not of interest; HNC, Head and neck cancer; mOS, Median overall survival; OS, Overall survival; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. NSCLC, Non-small cell lung cancer; RCC, Renal cell carcinoma; TNBC, Triple negative breast cancer.
Figure 1 PRISMA flow diagram. *60 unique studies included across the clinical, humanistic, and economic reviews, where 32 unique studies were not included as the outcomes were not of interest; HNC, Head and neck cancer; mOS, Median overall survival; OS, Overall survival; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. NSCLC, Non-small cell lung cancer; RCC, Renal cell carcinoma; TNBC, Triple negative breast cancer.CC BY · PubMed Central
Figure 2 Median overall survival (in months) by tumor type according to stage at diagnosis. Median overall survival of reported stages in bladder cancer, HNC, melanoma, NSCLC, RCC, and TNBC are presented as ranges in months with the purple circle representing the upper end of the range and the green circle representing the lowest end of the range. For RCC, single data point per stage has been identified and reported. Source: Bladder ( (48, 98–101)); HNC ( (95, 96)); melanoma ( (59, 60, 108)); NSCLC ( (64, 70, 81–83, 85–92)); RCC ( (114, 115)); TNBC ( (74, 103, 104)). Studies included are those from which outcomes could be extracted. For studies including assessing mOR for patients with RCC (n=2) (114, 115), OS results were based on risk stratification rather than cancer staging, and no study on RCC reported stage-wise distribution of OS. HNC, Head and neck cancer; NSCLC, Non-small cell lung cancer; RCC, Renal cell carcinoma; TNBC, Triple-negative breast cancer.
Figure 2 Median overall survival (in months) by tumor type according to stage at diagnosis. Median overall survival of reported stages in bladder cancer, HNC, melanoma, NSCLC, RCC, and TNBC are presented as ranges in months with the purple circle representing the upper end of the range and the green circle representing the lowest end of the range. For RCC, single data point per stage has been identified and reported. Source: Bladder ( (48, 98–101)); HNC ( (95, 96)); melanoma ( (59, 60, 108)); NSCLC ( (64, 70, 81–83, 85–92)); RCC ( (114, 115)); TNBC ( (74, 103, 104)). Studies included are those from which outcomes could be extracted. For studies including assessing mOR for patients with RCC (n=2) (114, 115), OS results were based on risk stratification rather than cancer staging, and no study on RCC reported stage-wise distribution of OS. HNC, Head and neck cancer; NSCLC, Non-small cell lung cancer; RCC, Renal cell carcinoma; TNBC, Triple-negative breast cancer.CC BY · PubMed Central
Figure 3 5-year OS rate by tumor type according to stage at diagnosis. Five-year survival rate of reported stages in bladder cancer, HNC, melanoma, NSCLC, RCC, and TNBC are presented as ranges in months, with the purple circle representing the higher end of the range and the green circle representing the lowest end of the range. For bladder cancer, a single data point per stage has been identified and reported. Source: Bladder ( (102)); HNC ( (54, 93, 94, 116)); melanoma ( (108)); NSCLC ( (63, 67, 70, 75, 76, 80, 89)); TNBC ( (74, 106, 107)). Studies included are those from which outcomes could be extracted. HNC. Head and neck cancer; NSCLC, Non-small cell lung cancer; TNBC, Triple-negative breast cancer.
Figure 3 5-year OS rate by tumor type according to stage at diagnosis. Five-year survival rate of reported stages in bladder cancer, HNC, melanoma, NSCLC, RCC, and TNBC are presented as ranges in months, with the purple circle representing the higher end of the range and the green circle representing the lowest end of the range. For bladder cancer, a single data point per stage has been identified and reported. Source: Bladder ( (102)); HNC ( (54, 93, 94, 116)); melanoma ( (108)); NSCLC ( (63, 67, 70, 75, 76, 80, 89)); TNBC ( (74, 106, 107)). Studies included are those from which outcomes could be extracted. HNC. Head and neck cancer; NSCLC, Non-small cell lung cancer; TNBC, Triple-negative breast cancer.CC BY · PubMed Central
Figure 4 Average PPPM costs in patients with TNBC and NSCLC by stage. Average PPPM costs of reported stages in NSCLC and TNBC are presented as ranges in US$ with the purple circle representing the higher end of the range and the green circle representing the lower end of the range. Source: NSCLC ( (65, 77, 117)); TNBC ( (74, 103, 120)). NSCLC, Non-small cell lung cancer; PPPM, Per patient per month; TNBC, Triple negative breast cancer.
Figure 4 Average PPPM costs in patients with TNBC and NSCLC by stage. Average PPPM costs of reported stages in NSCLC and TNBC are presented as ranges in US$ with the purple circle representing the higher end of the range and the green circle representing the lower end of the range. Source: NSCLC ( (65, 77, 117)); TNBC ( (74, 103, 120)). NSCLC, Non-small cell lung cancer; PPPM, Per patient per month; TNBC, Triple negative breast cancer.CC BY · PubMed Central
Figure 5 Total costs at 6 months (HNC) and lifetime costs (bladder) according to stage at diagnosis. Total costs of reported stages in bladder cancer (lifetime costs) and HNC (at 6 months) are presented as ranges in US$ with the purple circle representing the higher end of the range and the green circle representing the lower end of the range. Source (55, 121):. *Study conducted in India hence the low total cost values. HNC, Head and neck cancer.
Figure 5 Total costs at 6 months (HNC) and lifetime costs (bladder) according to stage at diagnosis. Total costs of reported stages in bladder cancer (lifetime costs) and HNC (at 6 months) are presented as ranges in US$ with the purple circle representing the higher end of the range and the green circle representing the lower end of the range. Source (55, 121):. *Study conducted in India hence the low total cost values. HNC, Head and neck cancer.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 105 references

Research works printed but not linked: 7

  1. 15. Kuznar W. Targeted agents, immunotherapies are advancing to the adjuvant setting in solid tumors. Targeted Therapies Oncol. (2021) 10(12):32.
  2. 16. National Academies of Sciences Engineering and Medicine. Chapter: 9. Federal programs that support cancer prevention and early detection. In: Fulfilling the Potential of Cancer Prevention and Early Detection. Washington, DC: The National Academies Press; (2003).
  3. 50. Tulyaeva AB, Iztleuov YM, Balmagambe-Tova SK, Koyshybaev AK, Djussembekov ST, Aitmagambetova MA. Five-year survival in young patients diagnosed with gastric cancer comparing to the older groups in the Aktobe province of western Kazakhstan within 2013-2017. Minerva Medica;. (2019) 110(Suppl. 1; 2):86.30667207
  4. 80. Kalilani L, Chao J, Hogea C, Stojadinovic A, Giove TJ, Sun X, et al. Recent Estimates of Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) in the US (2010-2020). The International Society for Pharmacoeconomics and Outcomes Research (ISPOR). (2022) 25(1):S4.
  5. 103. Sieluk J, Haiderali A, Huang M, Yang L, Tryfonidis K, Hirshfield KM. SEER-Medicare study of early-stage triple-negative breast cancer: Real-world treatment patterns, survival, and expenditures 2010 to 2016. J Clin Oncol. (2020) 38(15). doi: 10.1200/JCO.2020.38.15_suppl.e125 · doi:10.1200/jco.2020.38.15_suppl.e125
  6. 110. Ramond A, Carroll R, Vekeria S, Nordstrom B. Investigating Secular Trends in the Survival of Melanoma Patients in England. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR. Value in Health (2021) 24:S40.
  7. 121. Aly A, Johnson C, Doleh Y, Shenolikar R, Hussain A. Lifetime costs of urothelial carcinoma by stage at diagnosis. J Managed Care Specialty Pharm. (2019) 25(3a):S31.

Cited by

See all 21

Metadata

Authors
Aguiar-Ibáñez, R., Mbous, Y. P. V., Sharma, S., & Chawla, E.
Affiliations
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • PAREXEL International (India) (IN)
Venue
Frontiers in Oncology
Published
2025-03-19
Volume
15
Pages
1546447-1546447
ISSN
2234-943X (ISSN-L)
OpenAlex
W4408621175
Cited by
17
References
107
Citations by year
2026: 13 · 2025: 4
FWCI
2.00
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
early cancer detection, cancer stage at diagnosis, cancer screening, overall survival, health-related quality of life, healthcare resource utilization, health care costs, bladder cancer, gastric cancer, head and neck cancer, melanoma, non-small cell lung cancer, renal cell carcinoma, triple-negative breast cancer, tumor grade

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessing the clinical, humanistic, and economic impact of early cancer diagnosis: a systematic literature review. https://app.cochat.ai/papers/10.3389/fonc.2025.1546447
The paper
Aguiar-Ibáñez, R., Mbous, Y. P. V., Sharma, S., & Chawla, E. (2025). Assessing the clinical, humanistic, and economic impact of early cancer diagnosis: a systematic literature review. Frontiers in Oncology. https://doi.org/10.3389/fonc.2025.1546447

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.